Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-mutant non-small-cell lung cancer, drawn from the whole corpus: 26 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No trial yet compares an oral HER2 inhibitor with an antibody-drug conjugate or settles the sequence.
Interstitial lung disease from trastuzumab deruxtecan is unpredictable and occasionally fatal.
HER2-amplified and HER2-overexpressing lung cancers without a mutation lack a defined standard.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Confirmed response rate 71% in 75 previously treated patients naive to HER2-directed therapy; 48% after a HER2 antibody-drug conjugate; FDA accelerated approval August 2025.
ORR ~64%; accelerated approval Nov 2025.
A milestone in how this cancer is treated.
Confirmed response rate 49.
A milestone in how this cancer is treated.